The Motley Fool

4 relentless compounding stars to buy today

Successful investing doesn’t need to be complicated.

If you have a long-term view, a huge amount of success can be had simply by sticking to the basics: buying solid, un-sexy companies at decent prices.

The growth of these companies often looks unremarkable – 6% here here, 8% there… maybe a 3% dividend – but as these businesses grow year-after-year, the incredible power of compounding will usually send the share price – and your wealth – soaring.

These types of companies are easy to overlook, but deserve to considered as a core part of an investment portfolio.

Although not technically a company I think iShares Global Consumer Staples ETF (ASX: IXI) – an exchange traded fund – is a great starting point. The fund holds some of the world’s biggest consumer brands which earn bundles of cash and can easily pass on price increases to consumers, compounding returns year, after year, after year.

Breathing device manufacturer ResMed Inc. (CHESS) (ASX: RMD) is in a similar position. The company has grown income before taxes at a compounded annual rate of 5% over the last five years and with a growing market for healthcare spending, along with regular reinvestment in research and development, the company still has a long way to go.

Like ResMed, utility software company Gentrack Group Ltd (ASX: GTK) pays out a regular, growing dividend and, with the help of a couple of acquisitions along the way, has grown EBITDA (Earnings Before Interest, Tax Depreciation and Amortization), at an annual compounded rate of 24% over the last five years. The company currently pays a nice 2.5% dividend and is targeting a long term organic EBITDA growth of 15% per year.

Finally, blood product company CSL Limited (ASX: CSL) is another company resilient to broad consumer economic cycles and an absolute compounding star. Not only does the company earn completely ridiculous returns on equity, over the last five years the company has pushed earnings per share up at a compounded 9% per year!

CSL looks more expensive relative to annual earnings, but with a history of staggering returns it’s easy to see why investors are willing to stump up a premium for the company.

Our Top 3 Blue Chip Shares for 2019 – NOW AVAILABLE!

You’re invited! For a limited time, The Motley Fool Australia is giving away an urgent new investment report detailing our 3 TOP BLUE CHIP SHARES to own in 2019.

So if you like trustworthy, stable, high-performing companies that pay fat fully franked dividends – we’ve got you covered!

Stock #1 is a beloved old Australian company turning its attention to high-margin businesses... and rapidly returning cash to shareholders with its hefty dividend...

While Stock #2 is an online powerhouse that’s rapidly gaining market share all around the globe... poised for years (or even decades) of tremendous growth...

Even better, Stock #3 offers a whopping 6.5% grossed-up dividend! Which beats the rates on term deposits right out of the water – and offers the potential for capital gains, too.

You can discover all three shares inside our new report right now. To scoop up your FREE copy, simply click the link below right now. But you will want to hurry – this free report is available for a LIMITED TIME ONLY!


Regan Pearson owns shares of GENTRACK FPO NZ.

You can follow him on Twitter @Regan_Invests.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia owns shares of iShares Global Consumer Staples ETF. The Motley Fool Australia has recommended GENTRACK FPO NZ and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

One ASX Stock For An Estimated $US22 Billion Marijuana Market

A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.

And make no mistake – it is coming. To the tune of an estimated $US22 billion.

Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.

Here’s the best part: we think there’s one ASX stock that’s uniquely positioned to profit immensely from this explosive new industry… taking savvy investors along for what could be one heck of a ride.

AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.

Simply click below to learn more on how you can profit from the coming cannabis boom.

Click here to find out more